Purple Innovation celebrates its 10th anniversary by launching Grid Day on November 7, a special event honoring its loyal community. The campaign includes mattress giveaways to original customers, exclusive showroom events, and holiday discounts on sleep accessories. This initiative, called Grid It Forward, aims to reward long-time users and encourage them to share the benefits of Purple's GelFlex Grid technology with loved ones. The mattress deliveries are planned for April 2027, with ongoing promotions through November including Black Friday and Cyber Monday sales.
Purple Innovation's Grid Day campaign is the subject here. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 06, 2026 20:41 WIB: out of 134 priced US stocks, 40 rose and 90 fell. Notable movers include FIGS at USD 19.65 with a -2.77% change and 93% sell order activity, ATER at USD 0.83 with a +2.63% change and 66% buy order activity, and HD at USD 341.00 with a -2.55% change and 55% buy order activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
